Daunorubicin - CAS 20830-81-3
Not Intended for Therapeutic Use. For research use only.
Category:
ADCs
Product Name:
Daunorubicin
Catalog Number:
20830-81-3
Synonyms:
RP13057
CAS Number:
20830-81-3
Description:
Daunorubicin(RP13057) inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM.
Molecular Weight:
527.52
Molecular Formula:
C27H29NO10
COA:
Inquire
MSDS:
Inquire
Tag:
ADCs Cytotoxin
Chemical Structure
CAS 20830-81-3 Daunorubicin

Related ADCs Cytotoxin Products


CAS 522-97-4 DL-Tetrahydroberberine

DL-Tetrahydroberberine
(CAS: 522-97-4)

Tetrahydroberberine is a protoberberine alkaloid which potently block functional KATP channels natively expressed on midbrain dopamine neurons. Tetrahydroberber...

3-beta-iodo-Imperialine

Cervane alkaloid derivative of Imperialine from the plant Petilium eduardi. A selective M2 muscarinic receptor antagonist.

Dihydroatisine HCl

An antiarrhythmic of 1-st and 1Y classes and a blocker of TTX sensitive Na+ channels, Ca++ antagonist diterpene alkaloid from Delphinium staphisagria.

CAS 4540-25-4 Fillalbin

Fillalbin
(CAS: 4540-25-4)

Tropane alkaloid, from plants of the Convolvulus genus,

CAS 491-70-3 Luteolin

Luteolin
(CAS: 491-70-3)

Anti-inflammatory, antioxidant and free radical scavenger. Inhibits LPS-induced TNF-α, IL-6 and inducible nitric oxide production and blocks NF-κB and AP-1 acti...

CAS 90-47-1 Xanthone

Xanthone
(CAS: 90-47-1)

Xanthonoid Purified from Hypericum perforatum

Glutasam
(CAS: 148822-98-4)

Complex of lanthanide element,an anticoagulant. The lanthanide element from Glutasam replaces calcium in its complex with prothrombine, thus preventing the form...

Nanophine
(CAS: 5072-45-7)

Synthetic.alkaloid, a neuronal nicotinic AChR antagonist. Ganglioblocker.

CAS 57734-70-0 Bicarphen

Bicarphen
(CAS: 57734-70-0)

Diamine oxidase activator. Na+ channels blocker.

CAS 9083-23-2 Erabutoxin B

Erabutoxin B
(CAS: 9083-23-2)

an antagonist of the nicotinic acetylcholine receptor at the neuromuscular junction. Erabutoxin B from Laticauda semifasciata (Sea Snake)

Seco-DuocarmycinDME

Seco-Duocarmycin DME is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates.

CAS 57345-44-5 NMQ-OAc

NMQ-OAc
(CAS: 57345-44-5)

Bicyclic analog of Ach, a weak muscarinic AChR agonist.

CAS 224790-70-9 Cloflubicyne

Cloflubicyne
(CAS: 224790-70-9)

Cloflubicyne is a potent non-competitive GABA antagonist, convulsant, laboratory insecticide.

Seco-DuocarmycinDMA

Seco-Duocarmycin DMA is a cytotoxic agent, used as the cytotoxic component in antibody-drug conjugates.

CAS 5489-15-6 O-Methylisocorydine Iodomethylate

O-Methylisocorydine Iodomethylate
(CAS: 5489-15-6)

Aporphin alkaloid derivative of Isocorydine from plants of the Corydalis genus, Fumariaceae, a long-lasting ganglioblocker, with a sympathetic/parasympathetic a...

CAS 79580-28-2 Brevetoxin B

Brevetoxin B
(CAS: 79580-28-2)

Brevetoxin B is a polyketide neurotoxin produced by Karenia species and other dinoflagellates. It binds to site 5 on the alpha subunit of voltage-gated sodium c...

CAS 21059-47-2 Bucharaine

Bucharaine
(CAS: 21059-47-2)

Quinoline alkaloid, extracted from Haplophyllum bucharicum (Rutacae)

CAS 51486-74-9 Propybicyphat

Propybicyphat
(CAS: 51486-74-9)

Synthetic., a GABA-gated chloride channel blocker, non-competitive GABA antagonist in mammals.

CAS 935-22-8 Tempidine

Tempidine
(CAS: 935-22-8)

Potent ganglioblocker, a neuronal nicotinic AChR antagonist. .

M1-Nitrodienamine
(CAS: 113418-72-7)

Nitrodienamine, an inhibitor of Ca2+/Mg2+ ATPase.

Reference Reading


1. Adsorptive Stripping Voltammetric Determination of Low Levels of Daunorubicin
Joseph Wang,* Meng Shan Lin and Vince Villa. ANALYST, SEPTEMBER 1987, VOL. 112
The anthracycline antibiotic daunorubicin is a widely used anticancer drug, owing to its clinical efficacy against a wide range of malignancies. This drug was the first compound to show therapeutic effects in the treatment of leukaemia in man. The cytotoxic activity of daunorubicin against cancerous cells is hampered by dose-related cardiotoxic effects. Conse-quently, a highly sensitive analytical method is essential for the evaluation and administration of this drug. Various analytical methods have been employed for this purpose, including fluorescence, radioimmunoassayn and liquid chromatographic techniques. The complex redox activity of daunorubicin, and related anthracycline antibiotics, was investigated by Rao et aZ. who discussed the redox process in relation to the antineoplastic activity of these drugs. Anthracycline antibiotics contain two electroactive moieties: a reducible quinone group and an oxidisable hydroquinone centre. The reduction of the quinone group was used for polarographic measurements of the structurally similar anthracycline, Adriamycin, down to micromolar concentrations and for measuring the binding of anthracyclines to DNA. Trace amounts of daunorubicin have not yet been determined by voltammetric procedures.
2. Overview on in vitro and in vivo investigations of nanocomposite based cancer diagnosis and therapeutics
A. P. Subramanian, S. K. Jaganathan* and Eko Supriyanto. RSC Adv.,2015, 5, 72638–72652
Nanocomposite made of nano Fe3O4 and polylactide nanofibers loaded with daunorubicin to cause the induction of cell death of leukemia cancer cells was reported. The number of viable cells decreased when treated with the daunorubicin loaded nanocomposite. The cellular uptake was demonstrated by the inter-cellular green fluorescence emitted by the daunorubicin drug. The cell inhibition with the 9.93 *10-7 and 1.99 * 10-6 mol L-1 daunorubicin concentrations in the presence of Fe3O4 nanoparticles or PLA nanofibers produced no significant difference fromthat of the cell treated with daunorubicin alone. However, for daunorubicin concentrations at 9.93 * 10-7 and 1.99 * 10-6 mol L-1, the inhibition rates increased to 31% and 46% for the cell system cultured with daunorubicin and Fe3O4–PLA. Chen et al. developed a poly(lactic acid) (PLA) based nanocomposites for targeted drug delivery of daunorubicin to the leukemia K562 cells.
3. PEG–PLGA–PLL nanoparticles in combination with gambogic acid for reversingmultidrug resistance of K562/A02 cells to daunorubicin
Peipei Xu, Ruju Wang, Jian Li, Jian Ouyanga and Bing Chen*. RSC Adv.,2015, 5,61051–61059
Daunorubicin (DNR) is an effective chemotherapeutic agent which is widely used to treat leukaemia. However, DNR lacks specificity to cancer cells and can induce severe side effects. The development of MDR to DNR also hampered the clinical application of DNR. Therefore, new strategies are needed to overcome drug resistance and selectively deliver chemotherapeutic drugs to the tumour area with the aim of improving therapeutic efficacy.
4. Suitability of porous silicon microparticles for the long-term delivery of redox-active therapeutics
Elizabeth C. Wu, Jennifer S. Andrew, Alex Buyanin, Joseph M. Kinsellac and Michael J. Sailor*. Chem. Commun., 2011, 47, 5699–5701
Therefore, in using pSi as a drug delivery carrier, the redox chemistry of the material with the drug of interest must be considered, especially for molecules that are easily reduced. Anthracyclines such as doxorubicin and daunorubicin have been found to be effective against a wide range of human malignant neoplasms, but they display dose-limiting cardiotoxicity. This toxicity has been attributed to the in vivo reduction of the quinine moiety on the drug to a semiquinone free radical. The semiquinone can disproportionate to the hydroquinone, and further degradation of the compound can occur, potentially generating reactive oxygen radicals such as superoxide or hydroxyl radicals that can lead to DNA damage. Due to their structural similarity to benzoquinone, it is likely that anthracycline drugs will also undergo a redox reaction with a pSi host. Indeed, prior work on daunorubicin-loaded hydrosilylated pSi microparticles reported an uncharacterized degradation reaction in this reductive environment.